Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
SEED Therapeutics Enters Collaboration with Eisai for Novel Molecular Glue Degraders
Details : The SEED-Eisai Research Collaboration leverages Eisai’s expertise to advance the SEED early-stage product RBM39 for treating neurodegeneration and cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $1,500.0 million
August 06, 2024
Lead Product(s) : ST-00937
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at œTargeted Protein De...
Details : ST-00937, a new chemical entity (NCE) molecular glue that has already achieved IND Candidate status and will be advanced for the treatment of cancers in SEED’s first IND filing, as early as 2024.
Product Name : ST-00937
Product Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2023
Lead Product(s) : ST-00937
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The collaboration aims to discover and develop new chemical entities (NCEs) that could produce therapeutic benefit through targeted protein degradation (TPD).
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : $10.0 million
November 13, 2020
LOOKING FOR A SUPPLIER?